Ursodeoxycholic acid
- Generic Name
- Ursodeoxycholic acid
- Brand Names
- Reltone, Urso, Urso Forte
- Drug Type
- Small Molecule
- Chemical Formula
- C24H40O4
- CAS Number
- 128-13-2
- Unique Ingredient Identifier
- 724L30Y2QR
- Background
Ursodeoxycholic acid (UDCA), also known as ursodiol, is a naturally-occurring bile acid that constitutes a minor fraction of the human bile acid pool. UDCA has been used to treat liver disease for decades: its first use in traditional medicine dates back more than a hundred years. UDCA was first characterized in the bile of the Chinese black bear and is form...
- Indication
Ursodeoxycholic acid is indicated for the treatment of patients with primary biliary cholangitis.
It is used for the short-term treatment of radiolucent, noncalcified gallbladder stones in patients selected for elective cholecystectomy. It is also used to prevent gallstone formation in obese patients experiencing rapid weight loss.
- Associated Conditions
- Gallstones, Primary Biliary Cholangitis
- Associated Therapies
- -
The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2023-03-22
- Target Recruit Count
- 95
- Registration Number
- NCT05659654
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital,CAMS & PUMC, Tianjin, Tianjin, China
Ursodeoxycholic Acid in C. Difficile Infection
- Conditions
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Nottingham University Hospitals NHS Trust
- Target Recruit Count
- 6
- Registration Number
- NCT05526807
- Locations
- 🇬🇧
Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2022-09-28
- Target Recruit Count
- 1000
- Registration Number
- NCT05500937
- Locations
- 🇨🇳
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China
A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection
- Conditions
- Interventions
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2022-12-29
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05467553
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei, Taiwan
Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis
- Conditions
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
- Target Recruit Count
- 108
- Registration Number
- NCT05450887
- Locations
- 🇨🇳
Beijing Friendship Hospital, Beijing, China
Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients
- Conditions
- Interventions
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 102
- Registration Number
- NCT04977661
- Locations
- 🇪🇬
Hepatology, gastroenterology and infectious diseases department at Kafrelsheikh University Hospital, Cairo, Egypt
Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)
- Conditions
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT04956328
- Locations
- 🇨🇳
The first hospital of Jilin University, Changchun, Jilin, China
Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis
- Conditions
- Interventions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Hospital General Universitario de Alicante
- Target Recruit Count
- 332
- Registration Number
- NCT04924868
- Locations
- 🇪🇸
Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospital Clínico Universitario de Valencia, Alicante, Valencia, Spain
🇪🇸Hospital General Universitario de Elche, Elche, Alicante, Spain
Follow-up of NAFLD Patients With MRI-PDFF
- Conditions
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Asmaa Abdelfattah Elsayed
- Target Recruit Count
- 80
- Registration Number
- NCT04910178
- Locations
- 🇪🇬
Minya University Hospital, Minya, Egypt
Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 60
- Registration Number
- NCT04810156
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇰Odense University Hospital, Odense, Denmark
🇩🇰Herlev University Hospital, Herlev, Copenhagen, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.